Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services, Influenza Division, 330 Independence Avenue, SW RM G640, Washington DC, USA.
Expert Rev Vaccines. 2011 Aug;10(8):1183-94. doi: 10.1586/erv.11.82.
Influenza vaccines have been prepared in embryonated chicken eggs and used for more than 60 years. Although this older technology is adequate to produce hundreds of millions of doses per year, most viral vaccines are now being produced in cell culture platforms. The question of whether egg-based influenza vaccines will continue to serve the needs of the growing influenza vaccine market is considered here. In 2006, the US government committed to support the development of cell-based influenza vaccines by funding advanced development and expansion of domestic manufacturing infrastructure. Funding has also been provided for other recombinant DNA approaches that do not depend on growth of influenza viruses. As the influenza vaccine industry expands over the next 5-10 years, it will be interesting to follow which of these various technologies are able to best meet the needs of a growing influenza vaccine market.
流感疫苗已在鸡胚中制备并使用了 60 多年。尽管这种较旧的技术足以每年生产数亿剂疫苗，但现在大多数病毒疫苗都是在细胞培养平台上生产的。在这里考虑了基于鸡蛋的流感疫苗是否将继续满足不断增长的流感疫苗市场需求的问题。2006 年，美国政府承诺通过资助国内制造基础设施的先进开发和扩展来支持基于细胞的流感疫苗的开发。还为不依赖流感病毒生长的其他重组 DNA 方法提供了资金。随着流感疫苗行业在未来 5-10 年内的扩展，关注这些技术中哪些能够最好地满足不断增长的流感疫苗市场的需求将是一件有趣的事情。
